FI3618842T3 - Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä - Google Patents
Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä Download PDFInfo
- Publication number
- FI3618842T3 FI3618842T3 FIEP18730161.9T FI18730161T FI3618842T3 FI 3618842 T3 FI3618842 T3 FI 3618842T3 FI 18730161 T FI18730161 T FI 18730161T FI 3618842 T3 FI3618842 T3 FI 3618842T3
- Authority
- FI
- Finland
- Prior art keywords
- immunomodulatory compound
- cell therapy
- use according
- cells
- per day
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 93
- 230000002519 immonomodulatory effect Effects 0.000 title claims 91
- 238000002659 cell therapy Methods 0.000 title claims 63
- 210000001744 T-lymphocyte Anatomy 0.000 claims 70
- 210000004027 cell Anatomy 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 210000004369 blood Anatomy 0.000 claims 20
- 239000008280 blood Substances 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 9
- 230000000977 initiatory effect Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 7
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 7
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 230000007423 decrease Effects 0.000 claims 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- -1 8H9 Proteins 0.000 claims 4
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 3
- 108700012439 CA9 Proteins 0.000 claims 3
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 3
- 102100026497 Zinc finger protein 654 Human genes 0.000 claims 3
- 229950009563 avadomide Drugs 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 229960004942 lenalidomide Drugs 0.000 claims 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229960003433 thalidomide Drugs 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000599042 Homo sapiens Zinc finger protein Aiolos Proteins 0.000 claims 2
- 108010013958 Ikaros Transcription Factor Proteins 0.000 claims 2
- 102000017182 Ikaros Transcription Factor Human genes 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102000007298 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 102100032783 Protein cereblon Human genes 0.000 claims 2
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 208000026448 Wilms tumor 1 Diseases 0.000 claims 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims 2
- 101710127857 Wilms tumor protein Proteins 0.000 claims 2
- 102100037798 Zinc finger protein Aiolos Human genes 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 108010060273 Cyclin A2 Proteins 0.000 claims 1
- 102100025191 Cyclin-A2 Human genes 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 101150032879 Fcrl5 gene Proteins 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 102000010451 Folate receptor alpha Human genes 0.000 claims 1
- 108050001931 Folate receptor alpha Proteins 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims 1
- 208000025174 PANDAS Diseases 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims 1
- 240000000220 Panda oleosa Species 0.000 claims 1
- 235000016496 Panda oleosa Nutrition 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 101800001271 Surface protein Proteins 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 101001051488 Takifugu rubripes Neural cell adhesion molecule L1 Proteins 0.000 claims 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000003432 anti-folate effect Effects 0.000 claims 1
- 229940127074 antifolate Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 102000046935 human TNFRSF17 Human genes 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000003998 progesterone receptors Human genes 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492947P | 2017-05-01 | 2017-05-01 | |
| US201762538670P | 2017-07-29 | 2017-07-29 | |
| US201762549390P | 2017-08-23 | 2017-08-23 | |
| US201762580433P | 2017-11-01 | 2017-11-01 | |
| US201762596753P | 2017-12-08 | 2017-12-08 | |
| PCT/US2018/030545 WO2018204427A1 (en) | 2017-05-01 | 2018-05-01 | Combination of a cell therapy and an immunomodulatory compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3618842T3 true FI3618842T3 (fi) | 2023-12-15 |
Family
ID=62563245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18730161.9T FI3618842T3 (fi) | 2017-05-01 | 2018-05-01 | Soluterapian ja immunomodulatorisen yhdisteen yhdistelmä |
Country Status (19)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| WO2018132518A1 (en) | 2017-01-10 | 2018-07-19 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| US12049667B2 (en) | 2017-05-26 | 2024-07-30 | Abvitro Llc | High-throughput polynucleotide library sequencing and transcriptome analysis |
| CA3075716A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| US11066475B2 (en) * | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CN113573719A (zh) * | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| CN113747896A (zh) * | 2019-04-22 | 2021-12-03 | 斯塔顿治疗公司 | 来那度胺和其他免疫调节剂的连续递送 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| EP4054623A1 (en) * | 2019-11-07 | 2022-09-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione |
| JP7879804B2 (ja) * | 2019-12-06 | 2026-06-24 | フェイト セラピューティクス，インコーポレイテッド | 小化合物を使用するｉＰＳＣ由来エフェクター免疫細胞の増強 |
| WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
| CN115003818A (zh) * | 2020-01-22 | 2022-09-02 | 科济生物医药（上海）有限公司 | 病毒载体转导细胞的方法 |
| JP2023519099A (ja) * | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用 |
| US12655229B2 (en) * | 2020-03-18 | 2026-06-16 | Memorial Sloan Kettering Cancer Center | Anti-ceramide antibodies |
| IL297147B1 (en) * | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| CA3181399A1 (en) * | 2020-04-28 | 2021-11-04 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022137181A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Co-use of lenalidomide with car-t cells |
| CN113024671B (zh) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| IL307257A (en) * | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma |
| WO2023009700A2 (en) * | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Car-expressing immune cells that specifically target mesothelin and uses thereof |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| CA2305630C (en) | 1997-10-02 | 2012-11-06 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| TR200101500T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı. |
| NZ507886A (en) | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2000055134A1 (en) | 1999-03-18 | 2000-09-21 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US7615883B2 (en) | 2007-06-06 | 2009-11-10 | Meheen H Joe | Wind driven venturi turbine |
| EP2520643B8 (en) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| SG10202109752XA (en) * | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| EP3166968B1 (en) | 2014-05-02 | 2021-09-22 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| JP2017528433A (ja) * | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| BR112017005766B1 (pt) | 2014-09-22 | 2022-10-25 | Sacmi Cooperativa Meccanici Imola Societa' Cooperativa | Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
| US20180140602A1 (en) * | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| EP3770168A1 (en) * | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| SI3313818T1 (sl) * | 2015-06-26 | 2024-03-29 | Celgene Corporation | Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2017058754A1 (en) * | 2015-09-28 | 2017-04-06 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| EP3525803B1 (en) * | 2016-10-13 | 2022-12-07 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| CN109983027A (zh) * | 2016-10-20 | 2019-07-05 | 细胞基因公司 | 基于cereblon的可异二聚化嵌合抗原受体 |
| CA3042049A1 (en) * | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
| MA46716A (fr) * | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie |
| JP2019536460A (ja) * | 2016-12-03 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ−ｔ細胞の調節方法 |
| US20200078400A1 (en) * | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| US11590167B2 (en) * | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| CN109752300A (zh) | 2019-01-02 | 2019-05-14 | 五邑大学 | 一种涂料生产安全智能巡检机器人、系统及方法 |
-
2018
- 2018-05-01 PL PL18730161.9T patent/PL3618842T3/pl unknown
- 2018-05-01 PT PT187301619T patent/PT3618842T/pt unknown
- 2018-05-01 IL IL270250A patent/IL270250B2/en unknown
- 2018-05-01 IL IL310031A patent/IL310031A/en unknown
- 2018-05-01 EP EP18730161.9A patent/EP3618842B1/en active Active
- 2018-05-01 ES ES18730161T patent/ES2967467T3/es active Active
- 2018-05-01 JP JP2019559744A patent/JP7299841B2/ja active Active
- 2018-05-01 MA MA051871A patent/MA51871A/fr unknown
- 2018-05-01 WO PCT/US2018/030545 patent/WO2018204427A1/en not_active Ceased
- 2018-05-01 BR BR112019022893A patent/BR112019022893A2/pt unknown
- 2018-05-01 AU AU2018263887A patent/AU2018263887B2/en active Active
- 2018-05-01 CN CN201880042831.1A patent/CN111182909A/zh active Pending
- 2018-05-01 KR KR1020197035525A patent/KR102707505B1/ko active Active
- 2018-05-01 CN CN202410791051.4A patent/CN118948892A/zh active Pending
- 2018-05-01 US US16/609,733 patent/US20200078404A1/en active Pending
- 2018-05-01 SG SG11201910143T patent/SG11201910143TA/en unknown
- 2018-05-01 KR KR1020247030601A patent/KR20240139092A/ko active Pending
- 2018-05-01 DK DK18730161.9T patent/DK3618842T3/da active
- 2018-05-01 CA CA3061945A patent/CA3061945A1/en active Pending
- 2018-05-01 FI FIEP18730161.9T patent/FI3618842T3/fi active
- 2018-05-01 MX MX2019012975A patent/MX2019012975A/es unknown
- 2018-05-01 EP EP23203765.5A patent/EP4327878A3/en active Pending
-
2019
- 2019-10-31 PH PH12019502470A patent/PH12019502470A1/en unknown
-
2023
- 2023-06-16 JP JP2023098900A patent/JP7830386B2/ja active Active
-
2025
- 2025-07-22 AU AU2025206408A patent/AU2025206408A1/en not_active Abandoned
-
2026
- 2026-03-04 JP JP2026033824A patent/JP2026083262A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Callahan et al. | Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor | |
| JP7014731B2 (ja) | 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 | |
| Tsai et al. | A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies | |
| JP2020518591A5 (cg-RX-API-DMAC10.html) | ||
| JP2022512971A5 (cg-RX-API-DMAC10.html) | ||
| SG11202112452WA (en) | Methods for treating cancer | |
| WO2017201502A1 (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| JP2019536460A5 (cg-RX-API-DMAC10.html) | ||
| JP2014132009A5 (cg-RX-API-DMAC10.html) | ||
| JP7246309B2 (ja) | 免疫応答を調節するためのオキサビシクロヘプタン | |
| US12295962B2 (en) | Polymorphic compounds and uses thereof | |
| AU2019210332A1 (en) | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells | |
| JPWO2016204193A1 (ja) | 抗がん剤 | |
| JP2024529474A (ja) | キメラＴｉｍ４受容体およびその使用 | |
| JP2018504446A (ja) | がんを処置するためのｈｓｐ９０阻害剤およびｐｄ−１阻害剤の組み合わせ治療 | |
| US11878958B2 (en) | MEK inhibitors and uses thereof | |
| CA2969665A1 (en) | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) | |
| Cottini et al. | Novel therapeutic targets in multiple myeloma | |
| JP6754785B2 (ja) | 免疫治療投与レジメンおよびその組合せ | |
| D’Angelo | Manipulating the immune system with checkpoint inhibitors for patients with metastatic sarcoma | |
| US11696936B2 (en) | Treatment of cancer | |
| JP2023537762A (ja) | ポリ（ａｄｐ－リボース）ポリメラーゼの阻害剤と組み合わせたキメラｔｉｍ受容体を用いてがんを治療するための組成物および方法 | |
| WO2024218649A2 (en) | Combination of a protein kinase inhibitor with immunomodulatory agents | |
| Núñez | Biologic and Therapeutic Studies to Improve the Anti-tumor Efficacy of Antiangiogenic Tyrosine Kinase Inhibitors | |
| Reguera Núñez | Biologic and Therapeutic Studies to Improve the Anti-tumor Efficacy of Antiangiogenic Tyrosine Kinase Inhibitors |